Alkermes plc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value
Alkermes plc. (ALKS) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value of $500.00 thousand as of 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue · last filed 2026-07-28
- 2026-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $500.00K.
- 2025-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $500.00K.
- 2025-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $500.00K.
- 2025-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $500.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value |
|---|---|
| 2026-03-31 | $500.00K 10-Q · filed 2026-05-05 |
| 2025-12-31 | $500.00K 10-Q · filed 2026-07-28 |
| 2025-09-30 | $500.00K 10-Q · filed 2025-10-28 |
| 2025-06-30 | $500.00K 10-Q · filed 2025-07-29 |
| 2025-03-31 | $500.00K 10-Q · filed 2025-05-01 |
| 2024-12-31 | $0.00 10-K · filed 2025-02-12 |
| 2024-09-30 | $0.00 10-Q · filed 2024-10-24 |
| 2024-06-30 | $0.00 10-Q · filed 2024-07-24 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-01 |
| 2023-12-31 | $0.00 10-K · filed 2024-02-21 |
| 2023-09-30 | $0.00 10-Q · filed 2023-10-25 |
| 2023-06-30 | $0.00 10-Q · filed 2023-07-26 |
| 2023-03-31 | $0.00 10-Q · filed 2023-04-26 |
| 2022-12-31 | $0.00 10-K · filed 2023-02-16 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-02 |
| 2022-06-30 | $4.28M 10-Q · filed 2022-07-27 |
| 2022-03-31 | $3.94M 10-Q · filed 2022-04-27 |
| 2021-12-31 | $23.05M 10-K · filed 2023-02-16 |
| 2021-09-30 | $23.84M 10-Q · filed 2021-10-27 |
| 2021-06-30 | $29.06M 10-Q · filed 2021-07-28 |
| 2021-03-31 | $28.26M 10-Q · filed 2021-04-28 |
| 2020-12-31 | $33.43M 10-K · filed 2022-02-16 |
| 2020-09-30 | $47.18M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $47.02M 10-Q · filed 2020-07-29 |
| 2020-03-31 | $41.15M 10-Q · filed 2020-04-29 |
| 2019-12-31 | $34.35M 10-K · filed 2021-02-11 |
| 2019-09-30 | $31.46M 10-Q · filed 2019-10-23 |
| 2019-06-30 | $28.01M 10-Q · filed 2019-07-25 |
| 2019-03-31 | $38.37M 10-Q · filed 2019-04-25 |
| 2018-12-31 | $66.90M 10-K · filed 2020-02-13 |
| 2018-09-30 | $68.79M 10-Q · filed 2018-10-23 |
| 2018-06-30 | $64.22M 10-Q · filed 2018-07-26 |
| 2018-03-31 | $84.60M 10-Q · filed 2018-04-26 |
| 2017-12-31 | $86.19M 10-K · filed 2019-02-15 |
| 2017-09-30 | $80.56M 10-Q · filed 2017-10-26 |
| 2017-06-30 | $66.66M 10-Q · filed 2017-07-27 |
| 2017-03-31 | $66.37M 10-Q · filed 2017-04-27 |
| 2016-12-31 | $64.59M 10-K · filed 2018-02-16 |
| 2016-09-30 | $59.95M 10-Q · filed 2016-11-02 |
| 2016-06-30 | $60.77M 10-Q · filed 2016-07-28 |
| 2016-03-31 | $58.15M 10-Q · filed 2016-04-28 |
| 2015-12-31 | $57.12M 10-K · filed 2017-02-17 |
| 2015-09-30 | $62.98M 10-Q · filed 2015-10-29 |
| 2015-06-30 | $62.10M 10-Q · filed 2015-07-30 |
| 2014-03-31 | $1.31M 10-Q · filed 2014-04-30 |
| 2013-12-31 | $1.53M 10-K · filed 2015-02-24 |
| 2013-09-30 | $807.00K 10-Q · filed 2013-10-31 |
| 2012-12-31 | $0.00 10-Q · filed 2013-01-31 |
| 2012-09-30 | $1.74M 10-Q · filed 2012-11-01 |
| 2012-06-30 | $1.58M 10-Q · filed 2012-07-26 |
| 2012-03-31 | $10.66M 10-K · filed 2013-05-23 |
| 2011-03-31 | $1.05M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |